Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions.
Uloženo v:
| Název: | Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions. |
|---|---|
| Autoři: | Crawford, James M, Penberthy, Lynne, Pinto, Ligia A, Althoff, Keri N, Assimon, Magdalene M, Cohen, Oren, Gillim, Laura, Hammonds, Tracy L, Kapur, Shilpa, Kaufman, Harvey W, Kwasny, David, Liew, Jean W, Meyer, William A, Reynolds, Shannon L, Schleicher, Cheryl B, Subbiah, Suki, Theruviparampil, Catherine, Wallace, Zachary S, Warner, Jeremy L, Yoon, Suhyeon |
| Zdroj: | Open Forum Infectious Diseases; Jan2025, Vol. 12 Issue 1, p1-12, 12p |
| Témata: | SARS-CoV-2, COVID-19 pandemic, COVID-19, CHILD patients, HEMATOPOIETIC stem cells |
| Abstrakt: | Background We developed a United States–based real-world data resource to better understand the continued impact of the coronavirus disease 2019 (COVID-19) pandemic on immunocompromised patients, who are typically underrepresented in prospective studies and clinical trials. Methods The COVID-19 Real World Data infrastructure (CRWDi) was created by linking and harmonizing de-identified HealthVerity medical and pharmacy claims data from 1 December 2018 to 31 December 2023, with severe acute respiratory syndrome coronavirus 2 virologic and serologic laboratory data from major commercial laboratories and Northwell Health; COVID-19 vaccination data; and, for patients with cancer, 2010 to 2021 National Cancer Institute Surveillance, Epidemiology, and End Results registry data. Results The CRWDi contains 4 cohorts: patients with cancer; patients with rheumatic diseases receiving pharmacotherapy; noncancer solid organ and hematopoietic stem cell transplant recipients; and people from the general population including adults and pediatric patients. The project successfully linked and harmonized longitudinal, de-identified data on 5.2 million unique patients using privacy-preserving record lineage techniques. The system was developed in early 2024 and rapidly deployed, enabling longitudinal analysis of patient healthcare over the full geography of delivery settings and exploration of novel questions for populations at high risk for adverse outcomes. Conclusions The successful development of the CRWDi enables researchers to address unanswered questions that have arisen during the COVID-19 pandemic. By making the data broadly and freely available to academic researchers, this real-world data system represents an important complement to existing consortia and clinical trials that have emerged during the healthcare crisis and is readily reproducible for future purposing. [ABSTRACT FROM AUTHOR] |
| Copyright of Open Forum Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Databáze: | Biomedical Index |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science Buďte první, kdo okomentuje tento záznam!